1,076 reports of this reaction
2.2% of all FOSAPREPITANT DIMEGLUMINE reports
#3 most reported adverse reaction
PYREXIA is the #3 most commonly reported adverse reaction for FOSAPREPITANT DIMEGLUMINE, manufactured by Merck Sharp & Dohme LLC. There are 1,076 FDA adverse event reports linking FOSAPREPITANT DIMEGLUMINE to PYREXIA. This represents approximately 2.2% of all 48,249 adverse event reports for this drug.
Patients taking FOSAPREPITANT DIMEGLUMINE who experience pyrexia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PYREXIA is a less commonly reported adverse event for FOSAPREPITANT DIMEGLUMINE, but still significant enough to appear in the safety profile.
In addition to pyrexia, the following adverse reactions have been reported for FOSAPREPITANT DIMEGLUMINE:
The following drugs have also been linked to pyrexia in FDA adverse event reports:
PYREXIA has been reported as an adverse event in 1,076 FDA reports for FOSAPREPITANT DIMEGLUMINE. This does not prove causation, but indicates an association observed in post-market surveillance data.
PYREXIA accounts for approximately 2.2% of all adverse event reports for FOSAPREPITANT DIMEGLUMINE, making it one of the most commonly reported side effect.
If you experience pyrexia while taking FOSAPREPITANT DIMEGLUMINE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.